ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0899

Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial

Denis Poddubnyy1, Effie Pournara2, Agnieszka Zielinska3, Asta Baranauskaite4, Alejandro Muñoz Jiménez5, Sanchayita Sadhu6, Barbara Schulz2, Michael Rissler2, Chiara Perella2 and Helena Marzo-Ortega7, 1Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3Medycyna Kliniczna, Warszawa, Poland, 4Lithuanian University of Health Sciences, Kaunas, Lithuania, 5H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, 6Novartis Healthcare Private Limited, Hyderabad, Telangana, India, 7The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Biologicals, Disease-Modifying Antirheumatic Drugs (Dmards), pain, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early as Week (Wk) 8 in a broad population of patients (pts) with axial spondyloarthritis (axSpA; ankylosing spondylitis [AS] and non-radiographic [nr]-axSpA). Clinical studies in axSpA routinely use composite measures of disease activity to assess treatment effect, despite pain being the most troubling symptom for pts1–2. Here we present the 24-wk results from the SKIPPAIN study that evaluated the efficacy and safety of secukinumab (SEC) in reducing spinal pain and disease activity following a step-up dosing approach.

Methods: SKIPPAIN was a 24-wk, randomized, double-blind, multicenter, placebo (PBO)-controlled phase 3b study. Pts (aged ≥18 years) diagnosed with active disease defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥4 and average spinal pain numerical rating scale (NRS) score >4 at baseline and inadequate response to ≥2 NSAIDs ≥4 wks were enrolled. Pts were randomized (3:1) to receive subcutaneous SEC 150 mg or PBO wkly followed by every 4 wks (q4w) starting at Wk 4. At Wk 8, PBO pts were re-randomized to SEC 150 or 300 mg q4w up to Wk 24. Pts originally randomized to SEC 150 mg, were further classified as responders (spinal pain NRS score < 4) or non-responders (spinal pain NRS score ≥4) at Wk 8. Responders were re-assigned to continue double-blind treatment with 150 mg q4w up to Wk 24 (Arm A1). Non-responders were re-randomized to receive double-blind treatment with either 150 (Arm A2) or a step-up dose of 300 mg (Arm A3) q4w up to Wk 24. Primary endpoint was the proportion of pts achieving an average spinal pain score < 4 on a 0–10 NRS with SEC vs PBO at Wk 8. Change in spinal pain NRS and Ankylosing Spondylitis Disease Activity Score using C-reactive protein (ASDAS-CRP) scores at Wk 24 were exploratory endpoints.

Results: A total of 380 axSpA pts (269 [70.8%] AS and 111 [29.2%] nr-axSpA) were randomized to SEC 150 mg (N=285) or placebo (N=95). Primary endpoint of the study was met (proportion of spinal pain NRS (average) score responders: 32% vs 20% with an odds ratio [95% CI] of 1.9 [1.1, 3.3] favoring SEC vs PBO; P < 0.05). At Wk 24, further reductions in spinal pain were observed across treatment groups especially in those initially randomized to placebo and switched to active drug at Wk 8. Pronounced improvements were also observed in other disease activity measurements such as ASDAS-CRP score (Table and Figure). Of note, a numerically higher proportion of pts achieved ASDAS low disease activity at Wk 24 after SEC dose escalation at Wk 8 (Arm A3) as compared to those who remained on the same dose (Arm A2). No new or unexpected safety signals were reported.

Conclusion: Conclusion: SEC provided rapid, significant improvement in spinal pain and led to low disease activity in pts with axSpA. SEC dose escalation might be beneficial for pts not responding fully to the starting dose.

References:

  1. Danve A & Deodhar A. Clin Rheumatol. 2019; 38:625-34.
  2. Strand V, Singh JA. J Clin Rheumatol. 2017;23:383‐391.

Table. Spinal pain and ASDAS-CRP scores at Wks 8 and 24

Figure. Efficacy results at Wk 24


Disclosure: D. Poddubnyy, Eli Lilly and Company, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, BioCad, 5, Gilead, 5, GSK, 5, UCB, 5, 8, BMS, 8; E. Pournara, Novartis, 1, 3; A. Zielinska, Novartis, 5, Pfizer, 5; A. Baranauskaite, AbbVie, 5, 8, Novartis, 8, Amgen, 8, Roche, 8, KRKA, 8; A. Jiménez, None; S. Sadhu, Novartis, 3; B. Schulz, Novartis, 3; M. Rissler, Novartis, 1, 3; C. Perella, Novartis, 1, 3; H. Marzo-Ortega, Novartis, 2, 5, 8, Janssen, 2, 5, 8, Eli Lilly, 5, 8, Pfizer, 5, 8, UCB, 5, 8, AbbVie Inc., 5, 8, Celgene, 5, 8, Takeda Pharmaceutical Company, 5, 8.

To cite this abstract in AMA style:

Poddubnyy D, Pournara E, Zielinska A, Baranauskaite A, Jiménez A, Sadhu S, Schulz B, Rissler M, Perella C, Marzo-Ortega H. Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/secukinumab-provides-significant-improvement-of-spinal-pain-and-lowers-disease-activity-in-patients-with-axial-spondyloarthritis-24-week-results-from-a-randomized-controlled-phase-3b-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/secukinumab-provides-significant-improvement-of-spinal-pain-and-lowers-disease-activity-in-patients-with-axial-spondyloarthritis-24-week-results-from-a-randomized-controlled-phase-3b-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology